Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
Viktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, Shuyan Du, Bishu J Ganguly, Oumar Sy, Sun Ku Lee, Galina S Bogatkevich, Gary L Schieven, Elena Schiopu, Roberta Gonçalves Marangoni, Jonathan Goldin, Michael L Whitfield, John Varga, Viktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, Shuyan Du, Bishu J Ganguly, Oumar Sy, Sun Ku Lee, Galina S Bogatkevich, Gary L Schieven, Elena Schiopu, Roberta Gonçalves Marangoni, Jonathan Goldin, Michael L Whitfield, John Varga
Abstract
Background: There are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated interstitial lung disease (SSc-ILD).
Methods: Primary objectives were safety and pharmacokinetics. Secondary outcomes included clinical assessments, quantitative high-resolution computed tomography (HRCT) of the chest, serum biomarker assays and skin biopsy-based gene expression subset assignments. Clinical response was defined as decrease of >5 or >20% from baseline in the modified Rodnan Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169.
Results: Dasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No significant changes in clinical assessments or serum biomarkers were seen at six months. By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39% showed no progression of total ILD. Among 12 subjects with available baseline and post-treatment skin biopsies, three were improvers and nine were non-improvers. Improvers mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improvers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory gene expression subset was associated with higher baseline HRCT score (p = 0.0556). Non-improvers showed significant increase in lung fibrosis (p = 0.0313).
Conclusions: In patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile but no significant clinical efficacy. Patients in the inflammatory gene expression subset showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis during the study. These findings suggest that target tissue-specific gene expression analyses can help match patients and therapeutic interventions in heterogeneous diseases such as SSc, and quantitative HRCT is useful for assessing clinical outcomes.
Trial registration: Clinicaltrials.gov NCT00764309.
Conflict of interest statement
Competing Interests: VM, GSB, ES and RGM have no competing interests. GJK has received consulting fees from MedQIA LLC and has filed patents for quantitative imaging biomarkers in ILD. WH, SD, OS, SKL and GLS are employees of Bristol-Myers Squibb and own its stock. BJG is a former employee of Bristol-Myers Squibb and a current employee of Rinat/Pfizer. JG is a Founder of MedQIA LLC. MLW has filed patents for gene expression biomarkers in SSc, is a Scientific Founder of Celdara Medical LLC and has received consulting fees from Bristol-Myers Squibb. JV has received consulting fees from Bristol-Myers Squibb, Boehringer Ingelheim, Astellas, and research support from Bristol-Myers Squibb, Biogen, Novartis, Takeda and Cureveda. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
![Fig 1. CONSORT flowchart for the study.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g001.jpg)
![Fig 2. Drop plots of changes in…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g002.jpg)
![Fig 3. Representative pairs of baseline and…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g003.jpg)
![Fig 4. Intrinsic gene expression subset assignment…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g004.jpg)
Fig 5. Baseline and improver gene expression…
Fig 5. Baseline and improver gene expression and pathway enrichment analysis.
(A) 1,062 genes were…
Fig 6. HRCT trends across improvers and…
Fig 6. HRCT trends across improvers and non-improvers.
(A) QGG trends. (B) QLF trends. (C)…
- Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R. Tashkin DP, et al. Ann Rheum Dis. 2016 Feb;75(2):374-81. doi: 10.1136/annrheumdis-2014-206076. Epub 2014 Dec 1. Ann Rheum Dis. 2016. PMID: 25452309 Clinical Trial.
- Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP. Goldin JG, et al. Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC. Ann Am Thorac Soc. 2018. PMID: 30265153 Free PMC article. Clinical Trial.
- Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.Naidu GSRSNK, Sharma SK, Adarsh MB, Dhir V, Sinha A, Dhooria S, Jain S. Naidu GSRSNK, et al. Rheumatol Int. 2020 Feb;40(2):207-216. doi: 10.1007/s00296-019-04481-8. Epub 2019 Dec 7. Rheumatol Int. 2020. PMID: 31813058 Clinical Trial.
- Predictors of progression in systemic sclerosis patients with interstitial lung disease.Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM. Distler O, et al. Eur Respir J. 2020 May 14;55(5):1902026. doi: 10.1183/13993003.02026-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32079645 Free PMC article. Review.
- Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.Grosicka A, Manasar A, Kucharz EJ, Kotyla PJ. Grosicka A, et al. Best Pract Res Clin Rheumatol. 2018 Aug;32(4):541-549. doi: 10.1016/j.berh.2019.01.005. Epub 2019 Feb 14. Best Pract Res Clin Rheumatol. 2018. PMID: 31174823 Review.
- Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis.Noviani M, Chellamuthu VR, Albani S, Low AHL. Noviani M, et al. Front Med (Lausanne). 2022 Jun 30;9:911977. doi: 10.3389/fmed.2022.911977. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35847779 Free PMC article. Review.
- The promise of precision medicine in rheumatology.Guthridge JM, Wagner CA, James JA. Guthridge JM, et al. Nat Med. 2022 Jul;28(7):1363-1371. doi: 10.1038/s41591-022-01880-6. Epub 2022 Jul 4. Nat Med. 2022. PMID: 35788174 Free PMC article. Review.
- PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis.Paolini C, Agarbati S, Benfaremo D, Mozzicafreddo M, Svegliati S, Moroncini G. Paolini C, et al. Int J Mol Sci. 2022 Mar 31;23(7):3904. doi: 10.3390/ijms23073904. Int J Mol Sci. 2022. PMID: 35409263 Free PMC article. Review.
- Therapeutic molecular targets of SSc-ILD.Zhang Y, Distler JH. Zhang Y, et al. J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):17-30. doi: 10.1177/2397198319899013. Epub 2020 Jan 22. J Scleroderma Relat Disord. 2020. PMID: 35382225 Free PMC article.
- Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization.Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Kulkarni AS, et al. Aging Cell. 2022 Apr;21(4):e13596. doi: 10.1111/acel.13596. Epub 2022 Mar 27. Aging Cell. 2022. PMID: 35343051 Free PMC article. Review.
-
- Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117(3):557–567. doi: 10.1172/JCI31139 - DOI - PMC - PubMed
-
- Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol. 2010; 19(5):393–400. doi: 10.1111/j.1600-0625.2010.01082.x - DOI - PubMed
-
- Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007; 66(7):940–944. doi: 10.1136/ard.2006.066068 - DOI - PMC - PubMed
-
- McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57(2):318–326. doi: 10.1002/art.22532 - DOI - PubMed
-
- Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014; 66(8):1967–1978. doi: 10.1002/art.38702 - DOI - PMC - PubMed
- Clinical Trial, Phase II
- Multicenter Study
- Adult
- Aged
- Biomarkers / metabolism
- Dasatinib / administration & dosage*
- Female
- Gene Expression Regulation / drug effects*
- Humans
- Lung Diseases, Interstitial* / diagnostic imaging
- Lung Diseases, Interstitial* / drug therapy
- Lung Diseases, Interstitial* / etiology
- Lung Diseases, Interstitial* / metabolism
- Male
- Middle Aged
- Scleroderma, Systemic* / complications
- Scleroderma, Systemic* / diagnostic imaging
- Scleroderma, Systemic* / diet therapy
- Scleroderma, Systemic* / metabolism
- Skin* / diagnostic imaging
- Skin* / metabolism
- Tomography, X-Ray Computed*
- Biomarkers
- Dasatinib
- ClinicalTrials.gov/NCT00764309
- Full Text Sources
- Other Literature Sources
- Medical
![Fig 5. Baseline and improver gene expression…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g005.jpg)
Fig 6. HRCT trends across improvers and…
Fig 6. HRCT trends across improvers and non-improvers.
(A) QGG trends. (B) QLF trends. (C)…
![Fig 6. HRCT trends across improvers and…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5679625/bin/pone.0187580.g006.jpg)
References
- Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117(3):557–567. doi:
- Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol. 2010; 19(5):393–400. doi:
- Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007; 66(7):940–944. doi:
- McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57(2):318–326. doi:
- Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014; 66(8):1967–1978. doi:
- Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015; 1:15002 doi:
- Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009; 5(4):200–206. doi:
- Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354(25):2667–2676. doi:
- Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114(9):1308–1316. doi:
- Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009; 28(10):1285–1297. doi:
- Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, et al. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action. Mol Cancer. 2015; 14:199 doi:
- Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol. 2013; 9(11):1077–1090. doi:
- Hansell DM, Goldin JG, King TE Jr, Lynch DA, Richeldi L, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med. 2015; 3(6):483–496. doi:
- Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22(6):1200–1206. doi:
- Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2260–2270. doi:
- Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26(19):3204–3212. doi:
- Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95(2):232–240. doi:
- Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008; 22(7):2214–2222. doi:
- Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008; 58(5):1475–1484. doi:
- Cruz FF, Horta LF, Maia Lde A, Lopes-Pacheco M, Silva AB, Morales MM, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS One. 2016; 11(1):e0147005 doi:
- Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008; 127(3):330–339. doi:
- Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008; 111(3):1366–77. doi:
- Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008; 14(8):2484–2491. doi:
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581–590.
- LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202–205.
- Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995; 22(7):1281–1285.
- Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008; 36(7):1357–1364. doi:
- American College of Radiology. CT accreditation program. Testing instructions. Revised January 6, 2017. Available from: .
- Brown MS, Kim HJ, Abtin F, Da Costa I, Pais R, Ahmad S, et al. Reproducibility of lung and lobar volume measurements using computed tomography. Acad Radiol. 2010; 17(3):316–322. doi:
- Kim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010; 28(5 Suppl 62):S26–35.
- Kim HJ, Li G, Gjertson D, Elashoff R, Shah SK, Ochs R, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008; 15(8):1004–1016. doi:
- Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997; 169(4):977–983. doi:
- Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009; 136(5):1333–1340. doi:
- Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31(4):e15
- Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013; 133(8):1979–1989. doi:
- Chakravarty EF, Martyanov V, Fiorentino D, Wood TA, Haddon DJ, Jarrell JA, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2015; 17:159 doi:
- Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006; 38(5):500–501. doi:
- Gould J, Getz G, Monti S, Reich M, Mesirov JP. Comparative gene marker selection suite. Bioinformatics. 2006; 22(15):1924–1925. doi:
- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267–273. doi:
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–15550. doi:
- Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1(6):417–425. doi:
- Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011; 21(12):2455–2465. doi:
- Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther. 2012; 14(3):R102 doi:
- Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008; 3(7):e2696 doi:
- Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012; 132(5):1363–1373. doi:
- Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015; 11(1):e1004005 doi:
- Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016; 44(W1):W83–89. doi:
- Varga J, Roberson ED. Editorial: genomic advances in systemic sclerosis: it is time for precision. Arthritis Rheumatol. 2015; 67(11):2801–2805. doi:
- Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. Biochim Biophys Acta. 2013; 1832(7):897–904. doi:
- Korashy HM, Rahman AF, Kassem MG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014; 39:205–237. doi:
- Bristol-Myers Squibb. Sprycel® (dasatinib) highlights of prescribing information. Revised 09/2016. Available from: .
- Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008; 177(11):1248–1254. doi:
- Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009; 36(4):773–780. doi:
- Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol. 2007; 34(10):2056–2062.
- Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012; 55(9):2319–2326. doi:
- Fitter S, Vandyke K, Gronthos S, Zannettino AC. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol. 2012; 48(3):229–240. doi:
- Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, et al. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. 2015; 17:213 doi:
- Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008; 49(4):615–619. doi:
Source: PubMed